Online inquiry

IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3979MR)

This product GTTS-WQ3979MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets LTB&TNFSF14 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002341.2; NM_003807.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4050; 8740
UniProt ID Q06643; O43557
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3979MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5231MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ6673MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ14855MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ15829MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ15174MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA T1h
GTTS-WQ11835MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-4280
GTTS-WQ3208MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ5710MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW